Evaluation of the isokinetic muscle strength, balance and anaerobic performance in patients with young male hypogonadism

Aydoğan, Ümit; Eroğlu, Ali; Akbulut, Halil; Yıldız, Yavuz; Gök, Deniz Engin; Sönmez, Alper; Aydın, Taner; Bolu, Erol; Sağlam, Kenan

doi:10.1507/endocrj.ej11-0242

Cited by 14 publications

(14 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…To our knowledge, only one previous study has systematically evaluated the effects of TRT in HRPF in men with congenital hypogonadism, with results comparable to ours, especially regarding muscle performance. Aydogan, Eroglu et al., ; using a longitudinal experimental design, showed that a short‐acting intramuscular testosterone formulation significantly improved the isokinetic peak torque of knee extension in men with congenital hypogonadism to values similar to controls (Aydogan, Eroglu et al., ). In a cross‐sectional study, Maggio et al.…”

Section: Discussionmentioning

confidence: 99%

“…We then hypothesised that many signs and symptoms of testosterone deficiency may be associated with independently impaired HRPF components and may be differently restored by TRT. However, the efficacy of testosterone replacement in the retrieval of health‐related physical fitness in hypogonadal men remains elusive (Aydogan, Eroglu et al., ; Bhasin et al., ). In this context, congenital hypogonadotropic hypogonadism (CHH) represents a valuable model for studying the effects of testosterone on different health parameters in men, as it allows for the investigation of the effects of exogenous testosterone replacement exclusively, without a significant interference of endogenous secretion (Trabado, Lamothe, Maione, & Bouvattier, ).…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Health-related physical fitness and quality of life in men with congenital hypogonadotropic hypogonadism

et al. 2018

View full text Add to dashboard Cite

Congenital hypogonadotropic hypogonadism is a rare disorder characterised by impaired testosterone secretion since birth, and represents a valuable model for studying the effects of testosterone replacement therapy (TRT) in humans. This cross-sectional study aimed to investigate all health-related physical fitness (HRPF) components and quality of life in a series of eight men with hypogonadotropic hypogonadism under regular TRT. The study group was compared to a control group of 16 healthy subjects paired for age, body mass index and physical activity. Body composition, aerobic capacity, muscular strength and endurance, and joint flexibility were evaluated in two different 7-day interval time points, based on the pharmacokinetics of testosterone in the hypogonadal group. Quality of life was assessed by the WHOQOL-brief questionnaire. Both groups had similar performances in all HRPF components evaluated, independently of plasma testosterone levels (p > .05). Quality of life was also similar in the four domains analysed (p > .05). The results of this pilot study suggest that regular testosterone replacement was efficient in providing HRPF and quality of life in a series of congenitally hypogonadal men to levels like those observed in healthy men. In addition, acute fluctuations in plasma testosterone did not correlate with changes in muscle strength and endurance.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Health-related physical fitness and quality of life in men with congenital hypogonadotropic hypogonadism

et al. 2018

View full text Add to dashboard Cite

show abstract

“…It significantly impacts patients' quality of life [ 2 ]. Decreases in testosterone levels can lead to different degrees of pathophysiologic change in bone, muscle, fat, and the cardiovascular system [ 3 – 5 ]. Studies have found that male hypogonadism is caused by a variety of chronic diseases [ 6 – 8 ].…”

Section: Introductionmentioning

confidence: 99%

Risk Factors for Hypogonadism in Male Patients with Type 2 Diabetes

Ruan

Cao

et al. 2016

Journal of Diabetes Research

View full text Add to dashboard Cite

Background. Male hypogonadism is an endocrine disease characterized by low levels of serum testosterone and is closely related to the development of diabetes. The purpose of the present study was to observe the risk factors for hypogonadism in male patients with type 2 diabetes. Methods. A total of 213 patients with type 2 diabetes were enrolled and divided into a low total testosterone (TT) group (=75) and a normal TT group (=138). The patients' blood glucose, blood lipids, serum insulin, and sex hormones were measured. The correlations between the patients' metabolic index and sex hormone levels were analyzed. Results. Compared with the normal TT group, body mass index (BMI), fasting insulin (FINS), and HOMA insulin resistance index (HOMA-IR) levels were significantly higher, but the luteinizing hormone (LH) levels were significantly lower in the low TT group (p < 0.05). Correlation analyses found that TT was negatively correlated with BMI, waist circumference (WC), FINS, and HOMA-IR. TT was positively correlated with LH and follicle-stimulating hormone (FSH). Conclusions. Several risk factors of diabetes associated closely with hypogonadism. BMI, metabolic syndrome (MS), HOMA-IR, and LH are independent risk factors for hypogonadism in male patients with type 2 diabetes.

show abstract

“…3 Muscle weakness and low bone mass, Depression, anxiety loss of libido, and erectile dysfunction and decreased quality, abnormal lipid profile, CVS pathophysiologic change. [4][5][6][7] The association between low serum testosterone (LST) and diabetes (DM) has recently received substantial attention; studies have reported that male patients with Thus, it is unclear which the risk factors correlates in DM are associated with MHG, Therefore, it is especially important to explore the risk factors for hypogonadism to facilitate prevention, early diagnosis, and early treatment. The aim of this study was to determine the prevalence of male hypogonadism among Egyptian patients with type 2 diabetes and to identify the risk factors may be associated with low serum testosterone concentrations in men with type 2 diabetes.…”

Section: Introductionmentioning

confidence: 99%

“…[4][5][6][7] The association between low serum testosterone (LST) and diabetes (DM) has recently received substantial attention; studies have reported that male patients with ABSTRACT Background: Diabetes mellitus (DM) affects an estimated 285 million people worldwide. This number is expected to reach 438 million by the year 2030.…”

mentioning

confidence: 99%

Prevalence and predictors for low total testosterone levels among male type 2 diabetic patients: an Egyptian experience

Aboelnaga

Elshahawy

2016

Int J Res Med Sci

View full text Add to dashboard Cite

INTRODUCTIONDiabetes mellitus (DM) affects an estimated 285 million people worldwide. This number is expected to reach 438 million by the year 2030.1 On the other hand, Male hypogonadism (MHG) is a clinical syndrome that results from failure to produce physiological concentrations of testosterone. 2MHG is significantly associated with various comorbidities reduced libido, erectile dysfunction, increased adiposity, low energy and fatigue.3 Muscle weakness and low bone mass, Depression, anxiety loss of libido, and erectile dysfunction and decreased quality, abnormal lipid profile, CVS pathophysiologic change. [4][5][6][7] The association between low serum testosterone (LST) and diabetes (DM) has recently received substantial attention; studies have reported that male patients with ABSTRACT Background: Diabetes mellitus (DM) affects an estimated 285 million people worldwide. This number is expected to reach 438 million by the year 2030. The aim of this study was to determine the prevalence of male hypogonadism among Egyptian patients with type 2 diabetes and to identify the risk factors may be associated with low serum testosterone concentrations in men with type 2 diabetes. Methods: 140 male patients with type 2 diabetes were recruited in this cross-sectional study. This study WAS conducted from January 2012 to January 2016 in the endocrinology and metabolism unit, Mansoura University, Egypt. Results: We found 48 (34.2%) patients with hypogonadism (defined as TT ≤300 ng/dl) among 140 male patients with type 2 diabetes. 7 out of 48 (14.5%) patients with TT ≤300 ng/dl had high abnormal gondotrophins hormones levels while 41 patients out of 48 (85.5%) had normal gondotrophins hormones levels. We found BMI, WC, Hba1c, UACR, retinopathy ratio, nephropathy ratio, smoker ratio and patient on insulin therapy ratio were increased in the low TT group with statistically significance, but non statistically significant difference in age, diabetic duration, FSH, LH, Prolactin and lipid profile. In this study by using Pearson correlation, we found a statistically significant correlation between TT levels with BMI, WC, FSH, LH, Hba1c, and UACR (P value<0.05). Also by using stepwise multiple regression analysis, we found BMI, WC, LH, Hba1c, and UACR were statistically significant predictors of TT levels. In logistic regression analysis, we found Hba1c, UACR, and WC were statistically significant risk factors for MHG. Conclusions: Visceral obesity, higher Hba1c, and degree of albuminuria are independent risk factors for hypogonadism in Egyptian male patients with type 2 diabetes.

show abstract

Evaluation of the isokinetic muscle strength, balance and anaerobic performance in patients with young male hypogonadism

Cited by 14 publications

References 19 publications

Health-related physical fitness and quality of life in men with congenital hypogonadotropic hypogonadism

Health-related physical fitness and quality of life in men with congenital hypogonadotropic hypogonadism

Risk Factors for Hypogonadism in Male Patients with Type 2 Diabetes

Prevalence and predictors for low total testosterone levels among male type 2 diabetic patients: an Egyptian experience

Contact Info

Product

Resources

About